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EDITORIAL REVIEW
Low-renin hypertension
Recently much attention has been focused on
patients with essential hypertension and low plasma
renin activity (PRA), so-called "low-renin hyper-
tension". In 1964 Conn, Cohen and Rovner [1]
showed that patients with primary aldosteronism as a
cause of their hypertension had low or undetectable
levels of PRA, despite maneuvers which stimulate
renin release. As investigators searched for more
patients with primary aldosteronism, using low or
undetectable PRA as a marker, it became apparent
that most patients with low PRA had normal aldo-
sterone secretion (or excretion) and essential hyper-
tension. Since Helmer's original series [2] many cases
of low-PRA essential hypertension have been reported
[3—51]. This burgeoning literature has raised many
controversial and unanswered questions about the
incidence, etiology, prognosis and therapy of this type
of hypertension. Some of the critical issues we will
address are whether this represents a volume expansion
type of hypertension; whether an unidentified mineral-
ocorticoid accounts for this syndrome; what, if any,
its prognostic implications are; and how it should be
treated. In addition, the possibility will be considered
that low-PRA hypertension does not represent a
distinct disease entity with an etiology different from
essential hypertension with normal PRA.
Criteria for defining low-renin hypertension. Mea-
surement of PRA involves an assay of an enzymatic
reaction by performing either an immunoassay of
angiotensin I, the immediate end product, or a
bioassay of angiotensin II, the product of a second
enzymatic conversion. In addition to the amount of
renin actually present in the sample, the value obtained
is dependent on the concentration of renin substrate,
the presence of activators and inhibitors, the con-
ditions of the in vitro assay system and the techniques
used to measure either angiotensin I or II. In general
measurements of PRA using the bioassy of angio-
tensin II correlate well with data obtained utilizing
an immunoassay of angiotensin 1 [52]. Our purpose
will not be to review in detail the methodology and
pitfalls of the renin assay, which have been addressed
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in several recent publications [47, 53], but it must be
emphasized that variations in assay procedure may
account for some of the controversy in the literature.
In Helmer's original description of "low-renin
hypertension", PRA was measured largely under
random conditions and some measurements were
made after a standardized exercise. Since then the
physiology of renin release has been elucidated fur-
ther and its responsiveness to volume-mediated stimuli
has been recognized [54—56]. As a result, it became
apparent that PRA must be evaluated in relation to a
standard volume state and furthermore that hypo-
responsiveness can only be defined under conditions
which have been demonstrated to stimulate PRA in
normal subjects. Most investigators have utilized four
hours of upright ambulation following three days of a
sodium restricted diet as a standard stimulus to renin
release. Laragh's group has suggested evaluating
renin on random sodium intake in relationship to urine
sodium excretion, on the assumption that this reflects
dietary sodium intake [24]. They point out, however,
that low-PRA hypertensives are identified best at
levels of sodium excretion less than 150 mEq/day
[29]. Acute diuretic administration [11, 16, 57, 58] as
well as hypotensive stimuli [5, 10] have also been
utilized in an attempt to develop a more convenient
standardized approach to renin stimulation. It appears
that measurements made in the upright posture four
hours after the oral ingestion of 80 mg of furosemide
correlate well with identification of low PRA after a
low sodium diet [11, 16, 58]. Brunner et al have
criticized the use of furosemide; however, their data
were obtained in the supine position after 40 mg of
furosemide administered intravenously [28]. On the
other hand, it is clear that if diuretics are employed
the stimulus must be standarized and proved to
correlate with the results after sodium restriction,
since prolonged treatment with diuretics can result
in a rise in PRA even in low-PRA subjects [4, 6, 14,
17, 51]. In addition to demonstrating low PRA under
stimulated conditions, the definition of low-PRA
hypertension requires that primary aldosteronism be
excluded by appropriate measurements of either
plasma or urinary aldosterone. Furthermore, other
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known mineralocorticoid hypertensive states should
be considered also [27, 42, 59].
Relatively little attention has been given to repro-
ducibility in defining the low-PRA state. Crane, Harris
and Johns [23] found that 22% of 85 low-PRA
patients had normal-PRA responsiveness on retesting
and subgrouped their patients with consistently low
PRA. In the experience of Brunner et al [24] most
patients were evaluated twice and approximately one-
third did not have reproducible PRA profiles.' Genest
et a! have also mentioned that renin response may vary
in certain individuals [34]. These findings could reflect
either variability in the methodology for identifying
low PRA or variability in the renin responsiveness of
hypertensive patients at different points in time.
Studies designed specifically to test this latter possi-
bility have not been reported. This issue is critical
since a variable PRA during different times in a
hypertensive patient's course would suggest that low
PRA does not represent a marker for a distinct disease
entity, but rather a phase in the abnormality currently
classified as essential hypertension [46, 49].
Incidence: Age, race and sex characteristics. An
incidence of approximately 25% low-PRA values in
unselected hypertensive populations has been derived
from most analyses [23, 24]; however, the frequency of
low PRA in essential hypertension appears to depend
upon the age, sex and race of the study population as
well as the methods utilized to stimulate renin release.
The ages of low-PRA hypertensives have been reported
to be similar to [43] or older than [24, 33, 49] essential
hypertensive patients with normal- or high-PRA
values. The age of the patients is of considerable impor-
tance since it has been reported that the responsiveness
of PRA to stimuli decreases with age in normotensive
controls [44] and in hypertensive patients [49]. The
incidence of hyporesponsive PRA increases from 0%
in the 20 to 29 age group to 33°/ in the 70 to 79 age
bracket; however, PRA hyporesponsiveness appeared
mostly after age 50 in these normotensive subjects [44].
The age differences between the renin subgroups are
small and advanced age in the low-PRA subgroup
probably is not the sole explanation for the hypore-
sponsive PRA in most cases. Nonetheless, the afore-
mentioned studies point out the necessity of age-
matched controls when renin and aldosterone are
being studied.
Most large series have observed a female prepon-
derance in the low-PRA category of hypertensives. In
the report by Crane et al, the female to male ratio was
1 This calculation was based on analysis of Fig. 3 which shows
the ranges of the distribution of renin profiles [24]. Differing
sodium intakes may account for some of the failures of repro-
ducibility.
2:1 for 63 essential hypertensive patients who demon-
strated hyporesponsive PRA on two occasions [23].
In the series of 371 black hypertensive patients
reported by Mroczek, Finnerty and Catt, the % of
females was 76%, 64% and 5l% for low, normal and
high-PRA subgroups, respectively [43]. Brunner et al
did not give specific details about the preponderance
of females in the low-PRA group but they did com-
ment that "the three different renin subgroups
appeared to be evenly distributed according to sex"
[24]. No specific etiologic significance has been attached
to this female preponderance but it may have some
prognostic importance since actuarial data support
the belief that females tolerate hypertension better
than males [60].
There is also general agreement that black patients
have a greater incidence of low-PRA hypertension than
do white patients [6, 16, 24, 43]. The series of Mroczek
et al with 371 hypertensive patients, all of whom were
black, displayed an incidence of 42% with hyporespon-
sive PRA [43], an incidence higher than seen in series
of predominately white patients (Crane et al, 26%
[23]). Channick, Adlin and Marks [16] studied 100
unselected hypertensive patients and found suppressed
PRA in 26% of white and 5l% of black patients.
Brunner et al have recently detailed similar findings;
42% of 59 low-PRA hypertensives were black even
though only 27% of the entire study group of 219
cases were black [24]. The significance of the greater
frequency of hyporesponsive PRA in the black hyper-
tensive population is unknown. If low values of PRA
define a pathologic condition which explains or causes
the hypertension, then it must be concluded that black
patients have a predilection for this unknown disease.
If however the low values of PRA in some hyperten-
sives reflect variations in the response to elevated
blood pressure, then the overall responsiveness of the
renin system must be compared in normotensive
black and white subjects. Kern et a! [38] have recently
reported that furosemide stimulation of PRA was
significantly greater in normotensive whites than in
normotensive blacks and in hypertensive white
patients as compared to hypertensive black patients.
These data suggest but do not prove that black hyper-
tensive patients may have lower values of PRA because
of racial differences in the responsiveness of the juxta-
glomerular cells to various stimuli rather than a greater
incidence of some unknown disease. The sum of the
above-quoted data make it clear that normotensive
controls in any future studies of PRA in hypertension
must be matched for age, sex, and race with the
hypertensive propositi.
Etiology. The varying factors which influence
release of renin by the kidney have been considered in
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Table 1. Hypertension and renin suppression
1. Volume expansion
A. Primary renal sodium retention
B. High sodium intake
C. Mineralocorticoid excess
1. Hyperaldosteronism
2. Unidentified Mineralocorticoid(s) excess
3. Desoxycorticosterone excess
II. Decreased vascular capacitance
III. Increased effective angiotensin II activity in relation to PRA
A. Increased angiotensin II levels due to diminished
metabolic clearance
B. Increased receptor sensitivity to angiotensin II
IV. Inability to excrete potassium
V. Diminished beta-adrenergic activity
several excellent reviews of renin physiology [54, 55,
56]. They include effective vascular volume, blood
pressure, the renal nerves, sodium and potassium
homeostasis, and the circulating levels of catechola-
mines, estrogens, antidiuretic hormone and angio-
tensin II. Obviously, considering this lengthy list, it is
possible to conceive of a large number of aberations
which would result in a suppression of renin release.
On the other hand, the possibilities are restricted
significantly when circumstances are considered which
will simultaneously elevate the blood pressure and
suppress renin secretion. The major possibilities which
have been suggested are given in Table 1. Much of the
attention in the extensive literature on this subject has
focused upon a volume-expansion type of hyper-
tension particularly as a result of increased secretion
of some unidentified mineralocorticoid [21, 48, 61].
This represents a natural evolution in thinking since
primary aldosteronism is a well documented form of
low-PRA hypertension. Furthermore, the low-PRA
category of essential hypertension without overt
hyperaldosteronism was originally detected as an
outgrowth of an extensive search for a large undetected
group of hypertensives with primary aldosteronism.
Since volume expansion of any etiology can increase
blood pressure and decrease renin, other abnormalities
resulting in abnormal sodium retention have also
been proposed including a subtle renal lesion inhibiting
normal sodium excretion or a high sodium intake in
individuals genetically predisposed to hypertension,
analagous to salt-induced hypertension in a variety of
rat models [62]. It is therefore appropriate to consider,
in detail, the information available which bears on
whether low-PRA hypertension represents a volume-
expansion state.
The most convincing evidence for volume expansion
would be the direct demonstration of either an
expanded plasma or extracellular fluid (ECF) volume
(measured either as ECF volume or as exchangeable
sodium space). These methods are fraught with
difficulty, the major problem being the reference
point to use in defining normality, i.e., the relationship
to weight, body surface area, lean body mass, height3!
weight, etc. Nevertheless, these techniques have been
applied to the "reference" disease of volume-expansion
hypertension, i.e., primary aldosteronism, and it has
been possible to demonstrate with reasonable con-
sistency an increased plasma volume, ECF volume and
exchangeable sodium space in comparison with both
normal subjects and with essential hypertensives [45,
63—66].
On the other hand, the application of these same
techniques to low-PRA hypertensives has not, to date,
produced convincing evidence for volume expansion.
Plasma or blood volume measurements have been
reported by several groups. Helmer and Judson [6]
found an increase in mean blood volume when 13
low-PRA hypertensives were compared to 15 normo-
tensive subjects, but the difference was not significant
statistically. Similarly Jose, Crout and Kaplan [17]
found an increased mean but not significantly different
plasma volume in five low- as compared with seven
normal-PRA hypertensives, but in an earlier paper
they reported no differences between plasma volume
measurements of 11 low- and 36 normal-PRA hyper-
tensives [11]. Analysis of blood volumes from the data
of Birkenhager et al [67] reveals no difference in
mean values between 11 low- and 21 normal-PRA by-
pertensives, and Woods et al [12] reported comparable
plasma volumes in the low and normal-PRA patients
they evaluated.
A mean ECF volume (measured as radiosulfate
space) of 9.6 liter/rn2 in five low- as compared to 7.7
liter/m2 in seven normal-PRA hypertensives was
reported by Jose, Crout and Kaplan [17]. This in-
crease was statistically significant at the 1 %confidence
level; however, there is some question concerning
whether these groups were adequately matched for
body surface area.2 Furthermore, it is noteworthy that
in an earlier publication [11] this same group reported
equal values for ECF volume when 11 low- and 36
normal-PRA hypertensives were compared. In this
study the 36 patients in the normal-PRA group had an
ECF volume of 9.5 liters/m2, a value much higher
than the 7.7 liters/rn2 reported in the normal-PRA
patients described in their later paper; however, the
low-PRA values of 9.6 liters/rn2 were comparable.
2 Body surface area for the two groups of patients can be calcu-
lated from either the plasma or extracellular fluid volume data
which are expressed both in liters and in liters/rn2. The data are
consistent in the low-PRA group with a mean body surface area
of 1.82 m2. On the other hand, an inconsistency exists in the
normal renin group, body surface area equalling either 1.59 or
1.97 m2 depending on whether it is calculated from the plasma
or ECF volume data.
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They offer no explanation for these apparent dis-
crepancies.
Perhaps the most frequently quoted studies in
support of volume expansion was the paper of
Woods et al [121 who measured exchangeable sodium
in 9 low- and 5 normal-PRA hypertensives as well as in
14 matched normotensive controls. They found a
significantly greater exchangeable sodium space in the
low- compared to the normal-PRA hypertensives;
however, unlike the findings in hyperaldosteronism
the low-PRA group did not differ from their matched
normotensive controls. Surprisingly, the normal-PRA
group had a significantly smaller Na space than their
matched controls unlike most previous studies of
unselected hypertensives [65, 68—75]. Furthermore,
analysis of the exchangeable sodium data in the recent
publication by Schalekamp et al [45] indicates com-
parable values in 12 low- and 14 normal-PRA hyper-
tensive patients, while 17 patients with primary
aldosteronism had significantly increased spaces when
compared with either of these two groups as well as
compared to normal values. Of interest, six additional
low-PRA patients with elevated plasma DOC levels
also had normal exchangeable sodium spaces. To
summarize, when all the evidence available from
plasma, ECF and exchangeable Na spaces are con-
sidered, there is little which firmly supports an ex-
panded volume in the low-PRA hypertensives and it
appears clear that volume expansion comparable to
that found in primary aldosteronism does not exist.
Conclusions have been drawn about volume status
from observations of the responses to sodium loading
[12, 39, 76] or deprivation [6, 8, 17, 28, 37, 50] in the
various renin subgroups; however, the findings have
been inconsistent and contradictory. Of interest,
analyses of random urine collections for sodium have
not suggested that patients with low PRA ingest more
NaCl in their diet [25, 32].
The consistent observation that low-PRA hyper-
tensives respond to diuretics with a significantly greater
antihypertensive effect than normal-PRA hyperten-
sives has been interpreted as evidence supporting a
volume-expansion type hypertension. The impressive
and reproducible observation that spironolactone
(albeit at different dosage levels) exerted a greater anti-
hypertensive effect in low- as compared to normal-PRA
hypertensives [4, 17, 21, 26, 32, 33, 36, 51] and, in
addition, the similar effect of aminoglutethimide [12],
an inhibitor of adrenal steroidal synthesis, have been
interpreted as evidence favoring excess mineralo-
corticoid secretion in the etiology of this syndrome.
On the other hand, the observation by several groups
that the antihypertensive effect of other diuretics is also
greater in the low-PRA patients as well as comparable
to the effects of spironolactone [26, 36, 51, 77] has led
to the suggestion that this is simply a volume-mediated
hypertensive state.3 When the data have been reported,
the antihypertensive effect of these agents has been
associated with greater weight loss in the low-PRA
group [12, 21, 26, 32]. However, it should be noted
that in one study the fall in blood pressure correlated
with weight loss during spironolactone treatment but
not during hydrochiorothiazide treatment [26]. Al-
though this response to diuretics can be interpreted to
indicate that low-PRA hypertension is a volume-
mediated state, an alternative explanation could be
that for some reason (perhaps because of greater
aldosterone stimulation) normal-PRA hypertensives
are more difficult to diurese. To our knowledge there
are no studies comparing the effects on blood pressure
of a similar degree of volume contraction in normal-
and low-PRA hypertensives.
In addition to the response to spironolactone and
aminoglutethimide, other evidence interpreted as
favoring a mineralocorticoid etiology for low-PRA
hypertension has been cited. Some patients have been
found to have elevated levels of either urinary 18-OH
DOC [42] or plasma DOC [27], although the majority
of patients do not fall into either of these categories.
Salivary Na/K ratios are decreased in low-renin
patients in support of increased mineralocorticoid
activity [13, 16, 23]. In lieu of direct indentification of a
mineralocorticoid, the most impressive support for
this possibility would be a favorable response to
adrenalectomy. The only large series of adrenalec-
tomized patients was reported by Gunnells et al [19].
A significant percentage (79%) of their low-PRA
patients responded favorably to unilateral adrenalec-
tomy and the most impressive results were found in
those patients with both increased aldosterone excre-
tion and hypokalemia. All the patients who responded
to adrenalectomy had adenomas and/or hyperplasia
found in the adrenal glands. It seems clear that a large
percentage of their patients may have had primary
aldosteronism since most individuals had either a low
serum potassium or elevated aldosterone excretion.
Most groups have reported normal serum potassium
levels [5, 6, 11, 12, 14—17, 21—24, 27, 28, 33, 34, 37, 39,
43, 46, 49] and normal aldosterone excretion [12, 16,
17, 20, 22, 41] in their low-renin patients with essential
hypertension. Only 5 of the 32 patients reported in
the series of Gunnells et al had no clear-cut abnor-
mality in aldosterone and serum potassium. Three
of these five patients had adrenal pathology (a
hematoma in one) and a favorable response to surgery,
This observation apparently was not confirmed by one group
but their data have not been presented [48].
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while the other two had normal adrenal glands and no
hypotensive response to surgery [19]. There have been
other sporadic reports describing either adrenal patho-
logy or response to adrenalectomy in low-PRA
patients without hyperaldosteronism and the finding
of adrenal pathology and the response to surgery have
been variable [4, 16, 22, 23, 78]. This issue would still
appear to be a moot point.
Most observers agree that aldosterone excretion
(or secretion) is normal in low-PRA patients when it
is evaluated on a normal sodium diet [12, 16, 17, 20, 22,
41]. Excess secretion of some other mineralocorticoid
resulting in volume expansion and hypertension should
cause suppression of aldosterone secretion. This
observation, as well as normal potassium status, are
evidence contrary to the unidentified mineralocorticoid
thesis. On the other hand, in the low-PRA group
aldosterone may not stimulate normally in response to
sodium deprivation and may not suppress normally
during sodium loading [20, 22, 23, 49], suggesting the
possibility that these patients might represent an early
stage of primary aldosteronism. This lack of response
to sodium manipulation might be expected with other
etiologies also, since a blunted aldosterone response
might be anticipated due to the lack of PRA
responsiveness. Furthermore, Crane has recently
presented evidence indicating that plasma aldo-
sterone concentration suppresses normally in low-
PRA patients in response to immersion [44, 79],
suggesting that they do not represent examples of
subtle hyperaldosteronism. It is apparent that the
mineralocorticoid thesis, like the volume-expansion
concept, remains essentially undocumented.
The other mechanisms detailed in Table 1 have
received less attention. A decreased vascular capaci-
tance would be the alternative to volume expansion as
a means of increasing effective circulating volume but
this has not been specifically tested. An increase in
effective angiotensin II activity in relationship to the
measured PRA level could result either from diminished
metabolic clearance of angiotensin Ii or from an
increase in receptor sensitivity to angiotensin II. Both
of these possibilities appear unlikely since plasma
angiotensin II levels are not elevated [27] and the
pressor response to an exogenous angiotensin 11 load
has not suggested an increase in receptor sensitivity
[12, 15, 17].
Laragh recently suggested that an inability to
excrete potassium normally might result in this
picture [61]. Since potassium loading suppresses PRA
and stimulates aldosterone, abnormal potassium
retention could both diminish renin and result in a
volume-expansion type hypertension due to aldo-
sterone-mediated sodium retention. Little data are
available to support an aberation in potassium regula-
tion of this type. Serum potassium levels are usually
normal,4 exchangeable potassium is normal [12] and
the potassium excretory response to chronic sodium
loading is normal [22]. Brunner, Sealey and Laragh
[28] have presented data suggesting that low-PRA
hypertensives retain more potassium than normal-
PRA hypertensives when placed on a low sodium diet;
however, a statistical comparison between the potas-
sium retention of their low- and normal-PRA hyper-
tensives is not given and this finding was not confirmed
by another group [37]. Furthermore, they ascribed the
increased potassium retention to a blunted aldosterone
response, whereas their thesis proposes the opposing
alternative. Finally, although potassium loading
stimulates aldosterone secretion, its net effect is to
produce a natriuresis [80—82]. Volume contraction has
been documented both acutely and chronically during
high potassium intake [80—82]. Therefore, from the
data available it would appear that potassium reten-
tion is an unlikely explanation for low-PRA hyper-
tension.
The last alternative proposed is a blunted beta
adrenergic receptor system. Since renin release is
apparently mediated by beta adrenergic activity,
hyporesponsiveness of the beta adrenergic system
could explain blunted renin responsiveness. Hyper-
tension could conceivably result if peripheral and not
cardiac beta receptors were abnormal. Although
cardiac output would remain uninfluenced, the alpha
adrenergic vasoconstrictor influences on peripheral
vessels would be relatively unopposed by the beta
adrenergic vasodilator effect, resulting in unmodulated
vasoconstriction and an elevated blood pressure. No
consistent abnormality in daily excretion of urinary
catecholamines or their metabolic breakdown prod-
ucts has been detected in the low-PRA hypertensive
population [17, 22, 23]; however, this does not rule out
a specific beta receptor defect. This hypothesis, which
considers low PRA to be a marker of diminished beta
receptor activity (peripheral vascular and renal)
rather than a reflection of volume status will
require further investigation. Of interest in regard to a
possible role of the adrenergic nervous system in low-
PRA hypertensives are two reports that the rise in
urinary noradrenaline in response to upright posture is
blunted in low-PRA patients [40, 83]. Whether this
abnormality in catecholamine metabolism is a
primary or secondary phenomenon, and what role it
Although most patients with low PRA have serum potassium
values in the normal range, comparison as a group (N= 464)
withnormal PRA patients (N=714) in many large series reveals
slightly lower mean values (4.00 vs. 4.10 mM) [11, 12, 14, 16, 17,
21, 22, 24, 27, 28, 34, 37, 39, 43, 46, 49].
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Table 2. Incidence of vascular complications in essential hypertension
Author Low PRA
%,(N)°
Normal PRA
%,(N)
High PRA
%,(N)
Brunner et a! [24] 0(59) 11(124) 14(36)
Mroczek et a! [43] 11(157) 9 (169) 9 (45)
Genest et al [39] 24 (75) 15 (121) 67 (6)
Doyle et a! [84] 27 (22) 32 (76) 17 (18)
Amery et a! [85] 20 (20) 16 (19) 15 (20)
Gulati et a! [86] 15 (85) 5 (116) —
Christlieb et a! [87] 8 (25) 31(26) 29 (21)
Weinberger et a! [88] 32 (31) 43 (108)"
a % afflicted (total number at risk).
b Classified by author as "essential hypertension".
plays in the pathophysiology of this disorder, remains
to be elucidated.
Finally, as stressed earlier it is possible that hyper-
tension with low PRA might not represent a disease
entity with a distinct etiology but rather might reflect
a stage in the disease when renin suppression is more
intense, e.g., increased sensitivity to the renin sup-
pressive effects of elevated blood pressure, or a
response of a certain segment of the population to
an elevated blood pressure [46, 49]. Although the
identification of a new disease entity has attracted
the most attention, sight should not be lost of these
alternative explanations.
Prognosis. Recently Brunner et a! claimed that
patients with low-PRA hypertension have fewer
cerebrovascular accidents and myocardial infarcts
[24]. In this series of 219 patients, of whom 59
had low PRA, they found no strokes or myocardial
infarcts in the low-PRA category as contrasted with an
11% and l4% incidence in the normal- and high-PRA
categories, respectively. These data were interpreted as
consistent with the view that angiotensin is vasculo-
toxic and therefore the vascular consequences of hyper-
tension were thought to be greater if high PRA
(angiotensin) accompanied high blood pressure. Other
authors [34, 43, 84—88] have questioned these con-
clusions and Table 2 summarizes the findings of the
more detailed reports. Clearly, all the authors except
Brunner et a! [24] and Christlieb, Hickler and Lauler
[87] listed in Table 2 have observed a similar incidence
of cerebrovascular accidents and/or myocardial
infarcts in low-, normal- and high-PRA groups.
Genest et a! have also shown that in patients with renal
parenchymal or arterial types of hypertension, the
incidence of vascular complications is independent of
the PRA [34]. It is also noteworthy that Doyle et al
[84] evaluated 39 patients five years after determination
of PRA (measured prior to any use of antihyper-
tensive drugs) and found similar numbers of low-PRA
patients in groups with and without vascular complica-
tions, although it is bothersome that 20 of 39 patients
had vascular complications in this series. The recent
abstract by Christlieb et al supported Brunner's
original conclusion but no statistical evaluation
of the data was presented. These contrasting reports
have heightened debate which is unlikely to be
resolved easily. Some of the substantial problems
inherent in these analyses are as follows: 1) None of the
studies was prospective and hence the accuracy and
periods of observation varied. 2) Categorization of
patients into the low-PRA profile depended upon
different refill assays, different methods of stimulating
renin release (e.g. low sodium diet, furosemide, upright
posture) and possibly faulty control observations in
order to define normal PRA responsiveness. Conse-
quently, Brunner, Sealey and Laragh have questioned
the accuracy of the low-PRA profile in other series
[29]. 3) Assumptions about chronic vasculotoxicity of
renin (angiotensin) seem risky since the renin profile
was generally established two weeks after cessation of
antihypertensive medication whereas many (? most)
of these patients were treated over the years with
unknown effects on PRA. In other words, a patient's
chronic renin profile may differ substantially from the
initial profile since chronic administration of anti-
hypertensive drugs can raise or lower PRA. 4) Since it
is well established that adequate control of elevated
blood pressure will diminish cardiovascular and
cerebrovascular morbidity and mortality [89, 90], it is
imperative that studies relating prognosis to renin
profiles compare patients with similar degrees of con-
trol of their hypertension. Otherwise, the important
variables, namely pressure and plasma concentration
of angiotensin II, cannot be assessed separately. These
issues will on]y be resolved by a prospective, multi-
center, controlled experiment in which age, race and
sex are considered in the control group, in which renin-
stimuli and methods of assay are standardized and in
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which the stability of the renin profile is repeatedly
evaluated over several years in each patient.
Treatment. There appears to be general agreement
that patients with essential hypertension and low PRA
respond favorably to diuretic therapy [4, 21, 26, 32, 33,
36, 51, 77). Original claims that spironolactone
provided specific therapy, because of its antimineralo-
corticoid effect [21, 32] appear unsubstantiated since
subsequent studies have demonstrated that hydro-
chlorothiazide [26], hydrochlorothiazide-triamterene
[77] or chiorthalidone [36, 51] have as great an anti-
hypertensive effect as does spironolactone in low-PRA
patients. The antihypertensive effects of these agents
are presumably a result of negative sodium balance.
It is of practical therapeutic importance, regardless of
the mechanistic implications, that the overall respon-
siveness of the blood pressure to diuretic drugs in
low-PRA cases appears to be greater than in normal
or high-PRA categories. Diuretic therapy, in the low-
PRA group, can be expected to lower diastolic blood
pressure by 15 to 20 mm Hg [51, 77]. However, it
appears that those low-PRA patients with the highest
elevations of blood pressure may have the smallest
response to diuretics [51]. Conversely, Buhler et
a! have found the blood pressure decrement after
propranolol therapy to be least in the low-PRA
category and greatest in the high-PRA subgroup [30,
31]. These two observations may represent useful
therapeutic guides for planning the antihypertensive
therapy of the low-PRA hypertensive. It should be
emphasized, however, that the claims about a more
favorable prognosis for low-PRA patients have not
been clearly documented. Therefore, the important,
well established, fact that should guide therapy at the
present time is that reduction of blood pressure reduces
morbid events and improves prognosis in hyper-
tensive patients [89, 90].
Conclusions. Low or hyporesponsive PRA has been
found in approximately one-quarter of all patients with
essential hypertension and with increased prevalence
in blacks, women and older patients. The stability and
reproducibility of the low-PRA profile over a period of
months to years remains undocumented. If low PRA is
a marker for undiscovered primary causes of hyper-
tension, then this low-PRA profile should be stabile.
The etiology of low-PRA hypertension remains un-
known but many have invoked unidentified mineralo-
corticoids and unexplained volume expansion. There
is no persuasive evidence that either hypothesis is
correct. The possibility must be examined that low PRA
may represent a stage of, or response to, essential
hypertension rather than a distinct disease entity.
Some authors have concluded that patients with low-
PRA hypertension suffer fewer cerebrovascular and
cardiovascular accidents than normal- or high-PRA
patients. There is substantial evidence contradicting
this viewpoint, but a definitive resolution will require a
prospective carefully controlled study where the effects
of blood pressure can be separated from the adverse
effects of renin, i.e., angiotensin II. It appears that
diuretic therapy may be more useful in low-renin
hypertension, but considering our current knowledge,
the major therapeutic guideline should be effective
blood pressure control.
Michael J. Dunn
Richard L. Tannen
Burlington, Vermont
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